Market Pathways
✓

Market Pathways

OM DENNE PODKAST 🔗

Your premium guide to global medical device regulation, reimbursement and policy. Market Pathways delivers incomparable intelligence exploring the people, challenges, and opportunities impacting the global medtech regulatory and reimbursement community. View the latest issue of Market Pathways on MyStrategist.com
Sundhed & fitness
Medicin
Medicin
Verter:
Opdateringsfrekvens:
every 92 days
Gjennomsnittlig lydlængde:
44 minutes
Gæsteinterviews
Engelsk
USA
35 episoder
siden 1. juli 2021
episodic
BrugAPItil å hente denne podkast iJSON

I DENNE PODKAST 🔗

Redigér disse tags

NYESTE EPISODE 🔗

Ep. 35: MDR: Is Real Change on the Horizon?

Ep. 35: MDR: Is Real Change on the Horizon?

The need for important changes to MDR has been clear since its enactment in 2017. EU authorities have been reluctant to make substantive revisions, content to do nothing more than extend regulatory timelines. Now, however, there seems to be newfound resolve in Brussels to engage in fundamental refo…
00:52:44
DEL
LAGRE

SØK BLANT TIDLIGERE EPISODER

Søk etter gamle episoder av Market Pathways.
Integrer denne søgefelt på ditt nettsted

SISTE EPISODER

Ep. 34: What I Learned From 25 Years at CMS: An Interview With Tamara Syrek Jensen

Ep. 34: What I Learned From 25 Years at CMS: An Interview With Tamara Syrek Jensen

After a long career at CMS, including running the Coverage and Analysis Group for the past 10 years, Tamara Syrek Jensen can now candidly share her views on medical device reimbursement generally, particularly when it comes to Medicare. She provides a frank assessment on the systemic challenges, in…
00:45:40
DEL
LAGRE
Ep. 33: What Does it Mean to be a Reimbursement Professional?

Ep. 33: What Does it Mean to be a Reimbursement Professional?

Veteran medtech reimbursement executive Keely Scamperle talks about her newly launched Reimbursement and Market Access Professional Society, or RAMPSociety. She discusses the growth of reimbursement and market access as a distinct profession over her career and how she hopes the new group will help…
00:32:37
DEL
LAGRE
Ep. 32: The Tariff Challenge, Policy Optimism, and The MedTech Conference With Scott Whitaker

Ep. 32: The Tariff Challenge, Policy Optimism, and The MedTech Conference With Scott Whitaker

Scott Whitaker, president and CEO of AdvaMed, sits down with Market Pathways’ David Filmore to talk about hot topics in medtech policy, including the current situation with tariffs, future optimism for policies coming out of FDA and CMS, a Breakthrough Device coverage bill moving in Congress, AdvaM…
00:45:37
DEL
LAGRE
EP 31: Haven’t We Heard This Song Before? Major EU Regulatory Changes on the Horizon

EP 31: Haven’t We Heard This Song Before? Major EU Regulatory Changes on the Horizon

A special panel from our Innovation Summit Dublin conference in April 2025 Pedro Eerdmans, MD, PhD, Director, Global Strategy Services at NAMSA Tom Melvin, Associate Professor in Medical Device Regulatory Science, Institute for Clinical Trials, University of Galway; Chair, Biomedical Alliance in E…
00:44:20
DEL
LAGRE
BTIG Weighs In on Whether Trump Policies Can Dent MedTech’s Healthy Run

BTIG Weighs In on Whether Trump Policies Can Dent MedTech’s Healthy Run

By Wendy DillerFollowing a robust 2024, the medical device sector continues to thrive in 2025 and remains somewhat insulated from dramatic shifts in healthcare policies, at least in the short term. Market Pathways and MedTech Strategist writer Wendy Diller spoke on March 3, 2025 with Ryan Zimmerman…
00:29:54
DEL
LAGRE
Pioneering the Use of Real-World Evidence in Medtech: A Discussion with J&J’s Paul Coplan

Pioneering the Use of Real-World Evidence in Medtech: A Discussion with J&J’s Paul Coplan

The use of real-world evidence is increasing rapidly throughout the device industry. Here we talk with Paul Coplan, who is leading that effort at J&J, which received the first FDA-approved label extension using real-world evidence. Our conversation embraces the breadth of real-world evidence us…
01:06:17
DEL
LAGRE
FDA Inspections Getting Prepped and Avoiding Pitfalls

FDA Inspections Getting Prepped and Avoiding Pitfalls

FDA inspections are nobody’s idea of a good time. However, proper planning is crucial not only for ensuring baseline compliance, but also for establishing an effective corporate culture and building long-term company value. In this edition of Consultants Corner, we spotlight  advice from Jamie Harr…
00:31:44
DEL
LAGRE
A VC’s View of the Reimbursement Evolution: An Interview with Mike Carusi

A VC’s View of the Reimbursement Evolution: An Interview with Mike Carusi

Reimbursement has gone from being largely ignored to becoming top of mind for both product companies and investors. Mike Carusi was among the early proponents of understanding and improving the coding, coverage and payment processes. Here he takes us through the reimbursement evolution and delves i…
00:49:25
DEL
LAGRE
Reimbursement for Breakthrough Devices Still Lags—Need for TCET: An Interview with Josh Makower

Reimbursement for Breakthrough Devices Still Lags—Need for TCET: An Interview with Josh Makower

This discussion with Stanford Biodesign director and co-founder Josh Makower highlights a recent Stanford report that found the median time for initial coverage of breakthrough devices was nearly six years. Here we discuss how this data, much like information from previous Stanford reports, can hel…
00:56:25
DEL
LAGRE
Ansvarsfraskrivelse: Podkasten og kunstværket, det finnes indlejret på denne siden, er fra Market Pathways, som tilhører dens eier og ikke er tilknyttet eller godkjent av Listen Notes, Inc.
PODKAST SØGEMOTOR
Du kan bruke vår nettsted til å søke etter3,834,224podkaster og197,217,619episoder etter personer, steder eller emner.
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of giants.  ‐ Isaac "Llamacorn" Newton

ANBEFALINGER

Bruk API til å hente denne podkast